Company: CERO
Filing Date: 2025-02-13
Form Type: 424B3
Source: 0001213900-25-013493
Chunk: 2

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-13
Form: 424B3
Chunk 2
---
)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title                                     
 of each class                             |     | Trading   
 Symbol(s) |     | Name                                 
 of each exchange on which registered |
| Common Stock, par value                   
 $0.0001 per share                         |     | CERO      |     | NASDAQ Global Market                 |
| Warrants, each whole warrant              
 exercisable for one share of common stock |     | CEROW     |     | NASDAQ Capital Market                |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On February 5, 2025, CERo Therapeutics Holdings, Inc. (the “Company”) announced the pricing of a reasonable best efforts public offering (the “Offering”), with participation from a member of the Company’s board of directors and a single institutional investor, for the purchase and sale of (i) 2,551,020 shares of its common stock, par value $0.0001 per share (the “Common Stock”) or common stock equivalents in lieu thereof; and (ii) common warrants to purchase up to 2,551,020 shares of common stock (the “Warrants”), at a combined public offering price of $1.96 per share and Warrant. In connection with the Offering, on February 5, 2025, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with the investors. The Purchase Agreement contains customary representations, warranties and agreements of the Company and each investor and customary indemnification rights and obligations of the parties.

The Warrants have an exercise price of $1.96 per share, will be immediately exercisable upon stockholder approval and will have a term of exercise equal to five years following date of the initial exercise date. The exercise price and number of shares of Common Stock issuable upon exercise is subject to appropriate adjustment in the event of